ANGO
AngioDynamics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
15.75
▼ 0.07 (0.44%)
MARKET · —
Price
Open
15.37
Prev close
15.82
Day high
15.85
Day low
15.61
Volume
140.79K
Market cap
$650.99M
P/E (TTM)
—
52W range
9.39 – 16.29
Trailing performance
Returnvs SPY
1W
-0.63%
+0.7%
1M
+17.19%
+13.5%
3M
+31.69%
+28.6%
6M
+40.37%
+29.3%
YTD
+22.66%
+10.4%
1Y
+72.51%
+52.5%
3Y
+83.57%
+9.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$650.99M
Enterprise value$608.08M
Revenue (TTM)$320.17M
Gross profit$174.89M
EBITDA$188.00K
Net income$-36.74M
EPS (TTM)$-0.88
Free cash flow$21.77M
Total cash$53.86M
Total debt$10.96M
Book value / share$4.10
Shares outstanding41.33M
Float31.79M
Short % of float3.14%
Dividend yield—
Beta (5Y)0.32
Valuation & profitability ratios
Trailing P/E—
Forward P/E-350.00
PEG ratio1.41
Price / sales—
Price / book3.85
EV / revenue1.90
EV / EBITDA3,234.45
Gross margin54.62%
Operating margin-6.52%
Profit margin-11.48%
Return on equity-20.77%
Return on assets-5.13%
Debt / equity6.41
Current ratio2.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Total revenue | $320.17M | $292.50M | $303.91M | $338.75M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$36.74M | -$33.99M | -$184.35M | -$52.44M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net income | -$36.74M | -$33.99M | -$184.35M | -$52.44M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| May 2026 | -0.09 | -0.07 | +22.2% |
| Feb 2026 | -0.11 | 0.02 | +118.2% |
| Nov 2025 | -0.10 | 0.00 | +100.0% |
| Aug 2025 | -0.12 | -0.10 | +18.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.11 | 3 | $80.50M | +6.3% |
| Next quarter | -0.08 | 3 | $84.08M | +5.8% |
| Current year | -0.27 | 3 | $337.32M | +5.4% |
| Next year | -0.05 | 2 | $355.17M | +5.3% |
Analyst targets & ownership
Mean target$20.00
High target$24.00
Low target$17.00
Implied upside26.98%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders12.66%
Held by institutions94.08%
Institutions holding211
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+277.15K
Net buying
Buy transactions
17
300.52K shares
Sell transactions
1
23.37K shares
Net transactions
+18
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
5.23M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 30, 26 | NIGHAN WARREN G JR Officer |
SELL | 23.37K | $344.01K | Direct |
| Jul 22, 26 | CAMPBELL CHAD THOMAS Officer |
— | 6.47K | — | Direct |
| Jul 22, 26 | PICCININI LAURA Officer |
— | 8.05K | — | Direct |
| Jul 22, 26 | CLEMMER JAMES C Chief Executive Officer |
— | 52.36K | — | Direct |
| Jul 22, 26 | NIGHAN WARREN G JR Officer |
— | 5.69K | — | Direct |
| Jul 22, 26 | TROWBRIDGE STEPHEN A Chief Financial Officer |
— | 16.30K | — | Direct |
| Jul 15, 26 | JOHNSON WESLEY E JR Director |
STOCK | 11.89K | $0 | Direct |
| Jul 15, 26 | AUEN EILEEN O SHEA Director |
STOCK | 11.89K | $0 | Direct |
| Jul 15, 26 | REED JAN STERN J.D. Director |
STOCK | 11.89K | $0 | Direct |
| Jul 15, 26 | DONNELLY HOWARD W Director |
STOCK | 11.89K | $0 | Direct |
| Jul 15, 26 | NIGHAN WARREN G JR Officer |
STOCK | 17.97K | $0 | Direct |
| Jul 15, 26 | TARNOFF MICHAEL E Director |
STOCK | 11.89K | $0 | Direct |
| Jul 15, 26 | TROWBRIDGE STEPHEN A Chief Financial Officer |
STOCK | 53.26K | $0 | Direct |
| Jul 15, 26 | CAMPBELL CHAD THOMAS Officer |
STOCK | 16.08K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AUEN EILEEN O SHEA |
Director | 116.61K | Stock Award(Grant) |
CAMPBELL CHAD THOMAS |
Officer | 108.68K | Conversion of Exercise of derivative security |
CLEMMER JAMES C |
Chief Executive Officer | 862.45K | Conversion of Exercise of derivative security |
DONNELLY HOWARD W |
Director | 178.94K | Stock Award(Grant) |
JOHNSON WESLEY E JR |
Director | 155.43K | Stock Award(Grant) |
LAWRENCE WEISS T |
Officer | 112.62K | Stock Award(Grant) |
LICITRA KAREN A. |
Director | 102.32K | Stock Award(Grant) |
REED JAN STERN J.D. |
Director | 116.92K | Stock Award(Grant) |
TARNOFF MICHAEL E |
Director | 95.27K | Stock Award(Grant) |
TROWBRIDGE STEPHEN A |
Chief Financial Officer | 305.80K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
15.79
-0.25% from price
SMA 20
15.31
+2.85% from price
SMA 50
13.94
+13.00% from price
SMA 100
12.51
+25.92% from price
SMA 200
12.05
+30.70% from price
EMA 12
15.61
+0.89% from price
EMA 26
15.02
+4.87% from price
EMA 50
14.17
+11.13% from price
RSI (14)
64.7
Neutral
MACD (12,26,9)
0.59
Hist -0.04
ATR (14)
0.49
3.08% of price
Realised vol 30D
43.2%
Annualised
Bollinger upper
16.53
20, 2σ
Bollinger lower
14.10
20, 2σ
50 / 200 cross
Golden
13.94 vs 12.05
Trend bias
Above 200
+30.70%
Risk profile
Beta vs SPY
0.99
Less volatile than market
Correlation to SPY
0.30
Largely independent
Realised vol 30D
43.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-28.9%
Peak to trough
Max drawdown 5Y
-83.0%
Peak to trough
ATR 14
0.49
3.08% of price
Beta (reported)
0.32
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
12.50
-20.6% from spot
ATM implied vol
91.2%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
8
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
17.50
31 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
Zacks · 9d ago
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
MarketBeat · 11d ago
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
Zacks · 16d ago
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
Zacks · 16d ago
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
Zacks · 16d ago
AngioDynamics to Participate in Upcoming Investor Conferences
Business Wire · 25d ago
AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript
Motley Fool · 32d ago
AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
Zacks · 38d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.